Skip to contentO
Oncotelic Therapeutics, Inc.
O
OTLCOncotelic Therapeutics, Inc. Q1 2015 · 10-Q
Revenue—
Net Income-$2.77M-$2.77MN/M vs Q1 2014 EPS Diluted-$0.13-$0.13N/M vs Q1 2014 Operating Income-$2,777,000N/M Operating Cash Flow-$3,503,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Oncotelic Therapeutics, Inc. · CIK 908259 · Engraved from SEC EDGAR
ended Mar 31, 2015 · filed May 7, 2015 · 37 d after period end